BRPI1009919A2 - combinações de pentamidina para tratamento de câncer. - Google Patents
combinações de pentamidina para tratamento de câncer.Info
- Publication number
- BRPI1009919A2 BRPI1009919A2 BRPI1009919A BRPI1009919A BRPI1009919A2 BR PI1009919 A2 BRPI1009919 A2 BR PI1009919A2 BR PI1009919 A BRPI1009919 A BR PI1009919A BR PI1009919 A BRPI1009919 A BR PI1009919A BR PI1009919 A2 BRPI1009919 A2 BR PI1009919A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer treatment
- pentamidine
- combinations
- pentamidine combinations
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17480209P | 2009-05-01 | 2009-05-01 | |
| US29659010P | 2010-01-20 | 2010-01-20 | |
| PCT/IB2010/001012 WO2010125462A2 (en) | 2009-05-01 | 2010-05-03 | Pentamidine combinations for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1009919A2 true BRPI1009919A2 (pt) | 2017-03-28 |
Family
ID=43032617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1009919A BRPI1009919A2 (pt) | 2009-05-01 | 2010-05-03 | combinações de pentamidina para tratamento de câncer. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120128667A1 (pt) |
| EP (1) | EP2424516A4 (pt) |
| JP (1) | JP2012525371A (pt) |
| CN (1) | CN102573826A (pt) |
| AU (1) | AU2010243267A1 (pt) |
| BR (1) | BRPI1009919A2 (pt) |
| CA (1) | CA2758856A1 (pt) |
| NZ (1) | NZ596365A (pt) |
| RU (1) | RU2011142806A (pt) |
| WO (1) | WO2010125462A2 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9662308B2 (en) | 2008-02-01 | 2017-05-30 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Orally bioavailable pentamidine prodrugs for the treatment of diseases |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| WO2014008592A1 (en) * | 2012-07-13 | 2014-01-16 | Oncozyme Pharma Inc. | Combinations comprising diamidine compounds and parp inhibitors for use iν treating cancer |
| US20160222457A1 (en) | 2012-11-14 | 2016-08-04 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying malignant skin lesions |
| AU2013362755B2 (en) | 2012-12-21 | 2018-09-13 | Verlyx Pharma Inc. | Uses and methods for the treatment of liver diseases or conditions |
| ES2532150B1 (es) * | 2013-09-23 | 2015-11-30 | Universidad Autónoma de Madrid | Compuestos para el tratamiento del cáncer |
| US20170275700A1 (en) | 2014-08-14 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| MX381475B (es) | 2015-08-20 | 2025-03-12 | Ipsen Biopharm Ltd | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. |
| TWI778942B (zh) * | 2015-08-21 | 2022-10-01 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| EP3455761B1 (en) | 2016-05-10 | 2021-12-22 | Mayo Foundation for Medical Education and Research | Methods and materials for staging and treating skin cancer |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| CA3107401A1 (en) | 2018-07-25 | 2020-01-30 | Skylinedx B.V. | Gene signatures for predicting metastasis of melanoma and patient prognosis |
| MX2021007562A (es) | 2018-12-20 | 2021-09-28 | Auransa Inc | Analogos de pentamidina y usos para estos. |
| KR20210130765A (ko) * | 2019-02-22 | 2021-11-01 | 노보큐어 게엠베하 | Xelox, folfox 또는 이들의 각 구성 요소와 ttfield를 조합한 위암 치료 |
| CN111803475B (zh) * | 2019-04-10 | 2023-06-23 | 中美(河南)荷美尔肿瘤研究院 | 喷他脒在制备抑制pd1和pd-l1蛋白之间相互作用药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2327313T3 (es) * | 1999-11-16 | 2009-10-28 | Oncozyme Pharma Inc. | Pentamidina para el tratamiento del cancer. |
| US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| WO2003092616A2 (en) * | 2002-05-01 | 2003-11-13 | The Cleveland Clinic Foundation | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
| HRP20050115A2 (en) * | 2002-07-11 | 2005-10-31 | Combinatorx | Combinations of drugs for the treatment of neoplasms |
| PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| US20050054708A1 (en) * | 2003-07-28 | 2005-03-10 | Nichols Matthew James | Combinations of drugs for the treatment of neoplasms |
-
2010
- 2010-05-03 WO PCT/IB2010/001012 patent/WO2010125462A2/en not_active Ceased
- 2010-05-03 BR BRPI1009919A patent/BRPI1009919A2/pt not_active IP Right Cessation
- 2010-05-03 CA CA2758856A patent/CA2758856A1/en not_active Abandoned
- 2010-05-03 CN CN2010800193678A patent/CN102573826A/zh active Pending
- 2010-05-03 RU RU2011142806/15A patent/RU2011142806A/ru not_active Application Discontinuation
- 2010-05-03 AU AU2010243267A patent/AU2010243267A1/en not_active Abandoned
- 2010-05-03 NZ NZ596365A patent/NZ596365A/xx not_active IP Right Cessation
- 2010-05-03 US US13/318,197 patent/US20120128667A1/en not_active Abandoned
- 2010-05-03 JP JP2012507844A patent/JP2012525371A/ja active Pending
- 2010-05-03 EP EP10769389.7A patent/EP2424516A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2011142806A (ru) | 2013-06-10 |
| NZ596365A (en) | 2013-11-29 |
| US20120128667A1 (en) | 2012-05-24 |
| EP2424516A2 (en) | 2012-03-07 |
| WO2010125462A4 (en) | 2011-02-24 |
| CN102573826A (zh) | 2012-07-11 |
| JP2012525371A (ja) | 2012-10-22 |
| EP2424516A4 (en) | 2014-04-02 |
| WO2010125462A2 (en) | 2010-11-04 |
| WO2010125462A3 (en) | 2011-01-06 |
| AU2010243267A1 (en) | 2011-11-10 |
| CA2758856A1 (en) | 2010-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1009919A2 (pt) | combinações de pentamidina para tratamento de câncer. | |
| BR112012005594A2 (pt) | tratamento de câncer | |
| BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
| BRPI1010849A2 (pt) | parafuso para ossos. | |
| BRPI1013618A2 (pt) | pirimidinas substituídas para o tratamento de câncer | |
| BRPI1006075A2 (pt) | biomarcadores de cancer | |
| BR112012001490A2 (pt) | aparelho para alimentação. | |
| PT2456889E (pt) | Marcadores para o cancro do endométrio | |
| BRPI1010874A2 (pt) | composição para o tratamento de câncer de próstata | |
| BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
| EP2627333A4 (en) | Combination treatment of cancer | |
| BR112012000502A2 (pt) | terapia de combinação para o tratamento de diabetes | |
| BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
| BR112012002797A2 (pt) | tratamento de câncer de próstata | |
| BRPI0920952A2 (pt) | vaso de tratamento intregrado para correntes de resíduos | |
| BRPI1014802A2 (pt) | pró-fármacos de triptolida. | |
| BRPI0909016A2 (pt) | anticorpos úteis para o tratamento do câncer | |
| IT1396487B1 (it) | Convogliatore. | |
| BRPI0922367A2 (pt) | enzastaurin para o tratamento de câncer | |
| BRPI1008706A2 (pt) | dispositivo para diagnóstico. | |
| BRPI1009435A2 (pt) | tratamento para câncer no pâncreas | |
| BRPI1008016A2 (pt) | método para o tratamento de águas residuais | |
| SMT201600296B (it) | Lapatinib per il trattamento del cancro | |
| BRPI0918508A2 (pt) | orto-aminoanilidas para o tratamento de câncer | |
| BRPI1011786A2 (pt) | métodos para codificação artimética. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |